Prognostic factors following surgical resection of distal bile duct cancer

Young Jae Chung, Dong Wook Choi, Seong Ho Choi, Jin Seok Heo, Dong Hun Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Purpose: Prognostic factors for distal bile duct cancer are contentious. This study was conducted to analyze the prognostic factors of distal bile duct cancer after surgery with the aim of identifying those associated with diminished survival.

Methods: Two hundred forty-one patients who underwent pylorus-preserving pancreaticoduodenectomy (PPPD) or Whipple procedure in our tertiary hospital from February 1995 to June 2011 were retrospectively analyzed. All patients were pathologically proven to have distal bile duct adenocarcinoma. Postoperative complications, survival, and well-known prognostic factors after resection for distal bile duct cancer were investigated.

Results: Preoperative elevated carbohydrate antigen 19–9 (CA 19–9) level (P = 0.006), positive resection margin (P < 0.001), advanced T stage (P = 0.043), and lymph node metastasis (P = 0.002) were significantly independent worse prognostic indicators by multivariate analysis of resectable distal bile duct cancer.

Conclusion: R0 resection is the most important so that frozen sections should be utilized aggressively during each operation. For the distal bile duct cancer with elevated preoperative CA 19–9 level or advanced stage, further study on postoperative adjuvant treatment may be warranted.

INTRODUCTION

Malignant neoplasms of the bile duct are relatively rare. The annual incidence rate in western countries is 1–2 cases per 100,000. In Korea, the incidence rate was 3–4 cases per 100,000 in 2009, according to data from the National Cancer Information Center [1]. Incidence of bile duct cancer increases with the age. However, it grows slowly so that patients and physicians can be unaware of its presence in its early stages [2]. With growth, infiltration of adjacent vessels can easily occur, making a patient unresectable.

Bile duct cancer is anatomically classified as intrahepatic, perihilar and distal. Among them, distal bile duct cancer is the second most frequent [3]. However, its prognosis is better than the others, which can present symptoms including jaundice and cholangitis relatively early [4]. This can allow patients to be diagnosed early and surgically resected before the cancer advances.

Potential risk factors of distal bile duct cancer include age, sex, serum bilirubin, tumor markers, biliary drainage, operation time, amount of transfusion, surgeon’s experience, resection margin, tumor depth, perineural infiltration, tumor cell differentiation, stage of tumor, lymph node metastasis and complications [5–13]. To clarify the risk factors affecting survival from distal bile duct cancer, we reviewed 16
years surgeries of our facility.

**METHODS**

**Selection criteria**

Six hundred eighty-six patients were diagnosed with extrahepatic bile duct cancer at Samsung Medical Center between February 1995 and June 2011. At first 138 patients who had overlapping midportion or perihilar bile duct cancer and 14 patients whose cell type were not ductal adenocarcinoma of distal bile duct were excluded. To avoid confusion between middle and distal bile duct, the authors defined distal bile duct cancer that originating below the superior margin of pancreas head. 14 who were diagnosed other primary cancer earlier and four patients who were diagnosed another malignancy during the follow-up period were excluded. Inclusion criteria were pylorus-preserving pancreaticoduodenectomy (PPPD) and Whipple procedure for distal bile duct cancer, which were performed as curative intent and were confirmed as ductal adenocarcinoma by specialized pathologists in our hospital. One patient with distant metastasis operated with palliative intent was excluded consequently. Finally, 241 patients were enrolled.

**Data collection**

Data collection was achieved by reviewing electric medical records retrospectively. Follow-up day began on the operation day and ended on the last treatment day. We analyzed age, sex, preoperative carbohydrate antigen 19–9 (CA 19–9) level, preoperative serum total bilirubin, preoperative biliary drainage, types of biliary drainage, transfusion, tumor size, TNM staging and differentiation of cancer cell for recognized risk factors affecting survival postoperatively.

Preoperative biliary drainage such as percutaneous transhepatic biliary drainage (PTBD), endoscopic nasobiliary drainage (ENBD), and percutaneous transhepatic biliary drainage (PTBD) were performed for the patients with hyperbilirubinemia caused by biliary obstruction which were identified with preoperative imaging tools.

Adjuvant therapy was applied as concurrent chemoradiation manner. 5-Fluorouracil or gemcitabine or capecitabine were used as main chemotherapeutic agent and 44 Gy in 22 fractions were used for radiation. In palliative therapy, three ways such as chemotherapy only, radiation only and concurrent chemoradiation were carried out. The majority of them underwent chemotherapy with GEMOX (gemcitabine plus oxaliplatin) regimen or GP (gemcitabine plus cisplatin) regimen with or without radiation.

Resection margin was classified as R0, R1 and R2 whether tumor exists or not observed by macroscopically or microscopically. Macroscopic and microscopic tumor negative resection margin is considered as R0 resection. Macroscopic tumor negative and microscopic tumor positive resection margin is regarded as R1 resection. Macroscopic tumor positive resection margin is termed R2 resection. Transfusion was performed when patients’ hemoglobin level was under 8.5 g/dL or hypoxia induced by bleeding or unstable vital sign caused by sustained hemorrhage. We defined complication and mortality as which appeared within a month after the surgery. Postoperative pancreatic fistula was graded as A, B, or C according to an international study group on pancreatic fistula definition [14]. TNM staging of distal bile duct cancer based on American Joint Committee on Cancer (AJCC) 7th edition.

**Statistical analyses**

Overall survival and survival of each variable were calculated with Kaplan–Meier formula. Univariate analysis of risk factors affecting survival was calculated with log-rank test and multivariate analysis was calculated with Cox-regression model. We defined significant data as a P-value < 0.05 and used IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA) as a tool of statistical analysis.

**RESULTS**

**Demographics**

Average age of the 241 patients was 62.4 years (range, 31 to 88 years). There were 166 males (68.9%) and 75 females (31.1%). Table 1 shows that the patient’s chief complaint at the time of their first visit to our clinic. Jaundice was the most frequent symptom and was evident in 135 patients (56.0%), followed by abdominal pain (26.1%) and fever (5.4%). Preoperative biliary drainage was performed in 219 cases (90.9%). There were 115 cases of PTBD (52.5%), 80 cases of ENBD (36.5%), and 24 cases of ERBD (11.0%).

| Chief complaint                        | No. of patients (%) |
|----------------------------------------|---------------------|
| Jaundice                               | 135 (56.0)         |
| Abdominal pain                         | 63 (26.1)          |
| Febrile sensation                      | 13 (5.4)           |
| Indigestion                            | 12 (5.0)           |
| Weight loss                            | 6 (2.5)            |
| Nausea                                 | 5 (2.1)            |
| Melena                                 | 0 (0)              |
| Generalized weakness                   | 3 (1.2)            |
| Asymptomatic                           | 4 (1.7)            |
Pathologic characteristics

PPPD were performed in 171 patients and Whipple procedure were performed in 70 patients. 73 patients (30.3%) had lymph node metastasis. 6 patients were revealed to be R1 resection. Cancer cell was identified at the proximal margin of bile duct in five cases and at the soft tissue around superior mesenteric artery (SMA) in one case. R2 resection cases were four. One of them had portal vein invasion, one had SMA invasion, one had portal vein and SMA invasion and the last one showed proximal margin of bile duct invasion. Forty-one patients (17.5%) were pathologically confirmed as well differentiated form of ductal adenocarcinoma, 119 patients (50.9%) were moderate and 74 patients (31.6%) were poorly differentiated form. The last 7 patients had no pathological reports about tumor cell differentiation. According to AJCC 7th edition, stage I A were 11 cases (4.6%), stage IB were 42 cases (17.4%), stage IIA were 111 cases (46.1%), stage IIB were 61 cases (25.7%) and stage III were 15 cases (6.3%).

Table 2. Complications after major resection of distal bile duct cancer

| Complication                        | No. of patients (%) |
|-------------------------------------|---------------------|
| Pancreatic fistula                  | 11 (10.2)           |
| Bleeding                            | 15 (13.9)           |
| Delayed gastric emptying            | 6 (5.6)             |
| Anastomosis site leakage            | 8 (7.4)             |
| Iatrogenic diabetes mellitus        | 4 (3.7)             |
| Intra-abdominal fluid collection    | 40 (37.0)           |
| Chylous ascites                     | 6 (5.6)             |
| Pulmonary complication              | 3 (2.8)             |
| Major vessel problem                | 2 (1.8)             |
| Wound problem                       | 11 (10.2)           |
| Biliary stasis                      | 1 (0.9)             |
| Pancreatitis                        | 1 (0.9)             |
| Total                               | 108                 |

Table 3. Univariate analysis of predictors for survival in resected distal bile duct cancer

| Variable                          | No. of patients (%) | P-value |
|-----------------------------------|---------------------|---------|
| Age (yr)                           |                     |         |
| ≤60                               | 94 (39.7)           | 0.784   |
| >60                               | 143 (60.3)          |         |
| Sex                               |                     |         |
| Male                              | 162 (68.4)          | 0.509   |
| Female                            | 75 (31.6)           |         |
| Bilirubin at operation (mg/dL)    |                     |         |
| ≤1.6                              | 65 (27.4)           | 0.374   |
| >1.6                              | 172 (72.6)          |         |
| Biliary drainage                   |                     |         |
| Yes                               | 22 (9.3)            | 0.014   |
| No                                | 215 (80.7)          |         |
| Operation time (min)              |                     |         |
| ≤300                              | 66 (27.8)           | 0.371   |
| >300                              | 171 (72.2)          |         |
| CA 19-9 (U/mL)                    |                     |         |
| ≤35                               | 76 (32.1)           | 0.022   |
| >35                               | 154 (65.0)          |         |
| Transfusion                        |                     |         |
| Yes                               | 197 (83.1)          | 0.637   |
| No                                | 40 (16.9)           |         |
| Tumor size (cm)                   |                     |         |
| ≤2                                | 100 (42.2)          | 0.018   |
| >2                                | 134 (56.5)          |         |
| Resection margin                   |                     | <0.001  |
| Positive                          | 10 (4.2)            |         |
| Negative                          | 227 (95.8)          |         |
| Resperation                       |                     | 0.422   |
| Yes                               | 15 (6.3)            |         |
| No                                | 222 (93.7)          |         |
| Adjuvant therapy                  |                     | 0.024   |
| Yes                               | 77 (32.5)           |         |
| No                                | 157 (66.2)          |         |
| T stage                            |                     | <0.001  |
| T1                                | 11 (4.6)            |         |
| T2                                | 53 (22.4)           |         |
| T3                                | 158 (66.7)          |         |
| T4                                | 15 (6.3)            |         |
| N stage                            |                     | <0.001  |
| N0                                | 165 (69.6)          |         |
| N1                                | 72 (30.4)           |         |
| AJCC stage                         |                     | <0.001  |
| IA                                | 11 (4.6)            |         |
| IB                                | 42 (17.7)           |         |
| IIA                               | 108 (45.6)          |         |
| IIB                               | 61 (25.7)           |         |
| III                               | 15 (6.3)            |         |

CA 19-9, carbohydrate antigen 19-9; AJCC, American Joint Committee on Cancer.
62 cases (25.7%), stage III were 15 cases (6.2%), and stage IV was only one case but excluded as mentioned above.

Follow-up and complications
Complications within a month from the operation date were recorded (Table 2). One hundred eighty patients (44.8%) experienced various types of complications. The most frequent complication was intra-abdominal fluid collection (40 cases, 37.0%), which needed intervention or prolonged conservative treatment, followed by bleeding (15 cases, 13.9%). Three mortalities occurred as a consequence of postoperative bleeding and one mortality was caused by liver failure after left hepatic artery sacrifice during surgery.

The average follow-up period of 237 patients, during which four immediate postoperative mortality cases were excluded, was 31.3 months (range, 2 to 177 months). One hundred twelve patients (47.3%) experienced recurrence during the follow-up and one hundred twenty five patients (52.7%) had no follow-up recurrence. Among the 112 recurrent patients, local recurrence were 53 (47.3%), intrahepatic recurrence were 33 (29.5%), and systemic recurrence were 26 (23.2%). Eventually, 86 patients died because of the recurrence.

Adjuvant therapy was performed in 6 patients with stage IIA, 14 patients with stage IIB, and 3 patients with stage III. Despite of the adjuvant therapy, 13 patients recurred and died. Palliative therapy was conducted in 44 recurrent patients and 2 patients with R2 resection. Twenty-two patients, including one R2 resection case, showed partial response and survived during the follow-up. However 24 patients died after or during the palliative therapy. Only one patient was lost to follow-up.

Risk factors and survival
Four postoperative mortality cases were also excluded for survival analysis. The 3-, 5- and 10-year survival was 55.3%, 48.3% and 33.7%, respectively, after curative resection of distal bile duct cancer in our hospital (Fig. 1). Median survival duration was 73.0 months (range, 30.8 to 115.1 months). Univariate analysis revealed preoperative CA 19–9 >35 U/mL, tumor size >2 cm, presence of biliary drainage, complications, advanced stage and tumor cell differentiation and positive resection margin as poor prognostic factors (Table 3). In multivariate analysis, only CA 19–9, resection margin, T stage and N stage were significant factors (Table 4). Among them, positive resection margin was the strongest factor (hazard ratio, 5.078) indicating a negative influence on survival.

Survival difference between Whipple procedure and PPPD was presently evident (P = 0.006) (Fig. 2), despite the fact that their proportion of tumor staging was not significantly different (P = 0.659) (Fig. 3). For that reason, to rule out a cohort effect, we divided patients into four groups by period and by operation type. Patients who underwent Whipple procedure before 2003 were classified as group A and those who underwent the procedure after 2002 constituted group B. Patients underwent PPPD before 2003 were classified as group C and after 2002 were group D. When comparing groups A and B, it is obvious that the use of Whipple procedure had declined from 51 to 18 cases. On the other hand, PPPD had increased from 30 to 138 cases. There were no survival differences between groups A and C (P = 0.955). Groups B and
D also showed no survival differences ($P = 0.150$). However, survival of group D patients was significantly better than group C patients ($P = 0.001$) (Fig. 4).

**DISCUSSION**

In 1976, a classification of distal bile duct cancer in an anatomical order was proposed by Longmire [15]. He defined proximal bile duct cancer as that originating above the bifurcation of the cystic duct, middle bile duct cancer as that growing between the bifurcation of the cystic duct and the superior margin of pancreas and distal bile duct cancer as that emerging below the superior margin of the pancreas. It is difficult to discern middle bile duct cancer. Often they are not localized to the middle portion of the bile duct, but are otherwise spread to proximal or distal portion of the bile duct. Recently, concerning its extent of invasion, middle bile duct cancer was divided into proximal bile duct cancer and distal bile duct cancer [16]. The authors decided to include patients with distal bile duct cancer only, by excluding those proximal and middle ones.

The representative operations for curative resection of distal bile duct cancer are Whipple procedure and PPPD. To presently eliminate any influence caused by surgical technique and extent of cancer, we excluded patients who underwent other operations than those two major operations.

Several studies have reported appreciably different 5-year overall survival rates ranging from 16–52% of surgically resected distal bile duct cancer patients [17]. In our study,
the overall 5-year survival rate was 48.3% and the median survival duration was 73 months, which is comparable to other reports.

Serum CA19–9 is a well-known tumor marker of pancreatobiliary malignancies [18]. Generally it is not used as a prognostic or a diagnostic tool in clinical practice. Whether CA 19–9 might be an indicator of prognosis of bile duct cancer is debatable. Some retrospective studies reported that high serum levels of CA 19–9 have a close relationship with unresectability of the tumor [5]. However, in our study, serum CA 19–9 levels higher than 35 U/mL were associated with a significant survival disadvantage.

In univariate analysis, preoperative biliary drainage (P = 0.014) and tumor size larger than 2 cm (P = 0.018) had a negative effect on the survival. There are three ways to drain bile juice out of biliary tract: ERBD, ENBD, and PTBD. Subgroup analysis revealed that it is not necessary to distinguish the method used (ERBD and ENBD, P = 0.615; ERBD and PTBD, P = 0.100; ENBD and PTBD, P = 0.059). For that reason, we unified patients who had ERBD, ENBD and PTBD before the operation in the same group and compared them to another group in which drainage was not done. Although they did not have significant meaning in multivariate analysis, biliary drainage and larger tumor size might imply advanced tumor staging.

Lymph node status is a significant prognostic factor for distal bile duct cancer [19]. A study reported survival rate 65% without lymph node metastasis [20]. Also, our data showed that the survival rate 60% without lymph node metastasis and 17% with lymph node metastasis, which represents the survival significance of lymph node status of distal bile duct cancer. A Japanese study revealed that distal bile duct cancer patients with up to two positive lymph nodes had favorable prognosis [12]. Another Japanese group described that lymph node involvement is related to a high risk of liver metastasis [21].

Resection margin has been reported to be a significant prognostic factor, as it is the only factor that surgeons can control. Presently, resection margin displayed the highest hazard ratio (5.078). Therefore, it is necessary to obtain negative resection margin intraoperatively to improve survival.

This study had several limitations. As it was conducted in a single center and used a retrospective approach, selection bias may potentially have affected the results. However, the number of cases is large enough to calculate statistical values. Concerning node status, we did not analyze the number of metastasized nodes, which in any case does affect the surgical strategy.

In conclusion, as expected, surgical resection margin proved to be a significant indicator of worsened prognosis. Therefore, intraoperative frozen section should be utilized very aggressively to achieve R0 resection. For the distal bile duct cancer with elevated preoperative CA 19–9 level or advanced stage, additional study on postoperative adjuvant treatment may be warranted.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. The Korea Central Cancer Registry NCC. Annual report of cancer statistics in Korea in 2009. Seoul: Ministry of Health and Welfare; 2011.
2. Sako K, Seitzinger GL, Garside E. Carcinoma of the extrahepatic bile ducts: review of the literature and report of six cases. Surgery 1957;41:46–37.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
4. Tompkins RK, Thomas D, Wile A, Longmire WP Jr. Prognostic factors in bile duct carcinoma: analysis of 96 cases. Ann Surg 1981;194:447–57.
5. Fernandez-Ruiz M, Guerra-Vales JM, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol 2009;15:5279–86.
6. Allen PJ, Reiner AS, Gonen M, Klimstra DK, Blumgart LH, Brennan MF, et al. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. HPB (Oxford) 2008;10:341–6.
7. Bahra M, Jacob D, Langrehr JM, Neumann UP, Neuhaus P. Carcinoma of the distal and middle bile duct: surgical results, prognostic factors, and long-term follow-up. J Hepatobiliary Pancreat Surg 2008;15:501–7.
8. Choi HS. Assessment of the definition of early extrahepatic bile duct cancer through the prognosis analysis of patients who had received curative resection. Korean J Gastroenterol 2007;50:136–9.
9. Forsoo HM, Horn A, Viste A, Hoem D, Ovrebo K. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2008;7:412–7.
10. Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Predictors of survival in peripancreatic cancers following pancreaticoduodenectomy. Ann Surg Oncol 2010;17:591–7.
11. Choi YM, Cho EH, Lee KY, Ahn SI, Choi SK, Kim SJ, et al. Effect of preoperative biliary drainage on surgical results after pancreaticoduodenectomy in patients with distal common bile
duct cancer: focused on the rate of decrease in serum bilirubin. World J Gastroenterol 2008;14:1102-7.

12. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69-73.

13. Cho JY, Han HS, Yoon YS, Hwang DW, Jung K, Kim JH, et al. Preoperative cholangitis and metastatic lymph node have a negative impact on survival after resection of extrahepatic bile duct cancer. World J Surg 2012;36:1842-7.

14. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8-13.

15. Longmire WP Jr. Tumors of the extrahepatic biliary radicals. Curr Probl Cancer 1976;1:1-545.

16. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-73.

17. Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol 2011;2:94-107.

18. Yamaguchi K, Enjoji M, Nakayama F. Cancer of the extrahepatic bile duct: a clinicopathologic study of immunohistochemistry for CEA, CA19-9, and p21. World J Surg 1988;12:11-7.

19. Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg 1996;83:1712-5.

20. Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Tajima H, Miwa K. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999;229:76-83.

21. Sasaki R, Takahashi M, Funato O, Nitta H, Murakami M, Kawanura H, et al. Prognostic significance of lymph node involvement in middle and distal bile duct cancer. Surgery 2001;129:677-83.